Fmr LLC Lowers Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

FMR LLC cut its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 18.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 322,949 shares of the company's stock after selling 75,070 shares during the period. FMR LLC owned 0.61% of Stoke Therapeutics worth $3,969,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics in the second quarter valued at about $29,000. Nisa Investment Advisors LLC boosted its holdings in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company's stock valued at $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $123,000. Intech Investment Management LLC bought a new position in shares of Stoke Therapeutics during the third quarter worth approximately $160,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after purchasing an additional 1,994 shares during the period.

Insider Activity

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company's stock, valued at approximately $125,131,843.05. This trade represents a 17.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 13,945 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the completion of the transaction, the insider now owns 47,332 shares of the company's stock, valued at $604,902.96. The trade was a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,000,349 shares of company stock valued at $28,031,296 in the last three months. Company insiders own 11.30% of the company's stock.

Stoke Therapeutics Trading Down 2.1 %

STOK traded down $0.26 on Friday, reaching $12.06. The stock had a trading volume of 410,203 shares, compared to its average volume of 745,569. Stoke Therapeutics, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.58. The firm has a 50-day moving average of $12.49 and a 200-day moving average of $13.64. The company has a market capitalization of $638.82 million, a price-to-earnings ratio of -5.74 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analysts' expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on STOK shares. Leerink Partnrs raised Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.